Itraconazole in the treatment of aspergillosis: a study of 16 cases.
Itraconazole, a new triazole antifungal agent, has marked in vitro activity against filamentous fungi, particularly Aspergillus. We studied three groups of patients suffering from aspergillosis (16 cases): six affected with aspergilloma, three with allergic bronchopulmonary aspergillosis and seven with invasive aspergillosis. The survey consisted in clinical, radiological, mycological and serological evaluations with respect to drug plasma levels. Itraconazole was given at a dosage of 200-400 mg day-1 for periods ranging from 14 to 488 days. Out of the 16 patients, nine responded to therapy (recovery or improvement) and one failed to respond. Three patients improved but experienced relapses and three others could not be evaluated because of liver function disorders, so that treatment had to be stopped prematurely.
Lebeau
B
B
Service de Parasitologie-Mycologie, CHU, Grenoble, France.
Pelloux
H
H
Pinel
C
C
Michallet
M
M
Goût
J P
JP
Pison
C
C
Delormas
P
P
Bru
J P
JP
Brion
J P
JP
Ambroise-Thomas
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001228:Aspergillosis / Q000188:drug therapy*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy; D002648:Child; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000188:drug therapy
D017964:Itraconazole